Literature DB >> 32125955

Contrast-enhanced US for the Interventional Radiologist: Current and Emerging Applications.

Christopher D Malone1, David T Fetzer1, Wayne L Monsky1, Malak Itani1, Vincent M Mellnick1, Philip A Velez1, William D Middleton1, Michalakis A Averkiou1, Raja S Ramaswamy1.   

Abstract

US is a powerful and nearly ubiquitous tool in the practice of interventional radiology. Use of contrast-enhanced US (CEUS) has gained traction in diagnostic imaging given the recent approval by the U.S. Food and Drug Administration (FDA) of microbubble contrast agents for use in the liver, such as sulfur hexafluoride lipid-type A microspheres. Adoption of CEUS by interventional radiologists can enhance not only procedure guidance but also preprocedure patient evaluation and assessment of treatment response across a wide spectrum of oncologic, vascular, and nonvascular procedures. In addition, the unique physical properties of microbubble contrast agents make them amenable as therapeutic vehicles in themselves, which can lay a foundation for future therapeutic innovations in the field in drug delivery, thrombolysis, and vascular flow augmentation. The purpose of this article is to provide an introduction to and overview of CEUS aimed at the interventional radiologist, highlighting its role before, during, and after frequently practiced oncologic and vascular interventions such as biopsy, ablation, transarterial chemoembolization, detection and control of hemorrhage, evaluation of transjugular intrahepatic portosystemic shunts (TIPS), detection of aortic endograft endoleak, thrombus detection and evaluation, evaluation of vascular malformations, lymphangiography, and percutaneous drain placement. Basic physical principles of CEUS, injection and scanning protocols, and logistics for practice implementation are also discussed. Early adoption of CEUS by the interventional radiology community will ensure rapid innovation of the field and development of future novel procedures. Online supplemental material is available for this article. ©RSNA, 2020.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32125955     DOI: 10.1148/rg.2020190183

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  9 in total

Review 1.  Using Contrast-Enhanced Ultrasound to Characterize Focal Liver Lesions.

Authors:  David T Fetzer; Yuko Kono; Shuchi K Rodgers
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 2.  Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors.

Authors:  Arian Mansur; Tushar Garg; Apurva Shrigiriwar; Vahid Etezadi; Christos Georgiades; Peiman Habibollahi; Timothy C Huber; Juan C Camacho; Sherif G Nour; Alan Alper Sag; John David Prologo; Nariman Nezami
Journal:  Diagnostics (Basel)       Date:  2022-05-24

Review 3.  Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography.

Authors:  Agostino Inzerillo; Maria Franca Meloni; Adele Taibbi; Tommaso Vincenzo Bartolotta
Journal:  World J Hepatol       Date:  2022-04-07

4.  Contrast-enhanced ultrasound-guided musculoskeletal biopsies: our experience and technique.

Authors:  Steven P Daniels; Lori Mankowski Gettle; Donna G Blankenbaker; Kenneth S Lee; Andrew B Ross
Journal:  Skeletal Radiol       Date:  2020-09-15       Impact factor: 2.199

Review 5.  The Role of Percutaneous Ablation in the Management of Colorectal Cancer Liver Metastatic Disease.

Authors:  Dimitrios K Filippiadis; Georgios Velonakis; Alexis Kelekis; Constantinos T Sofocleous
Journal:  Diagnostics (Basel)       Date:  2021-02-14

Review 6.  Diagnosing Pancreatic Adenocarcinoma With Contrast-Enhanced Ultrasonography: A Literature Review of Research in Europe and Asia.

Authors:  Aaiz Hussain; Derek S Weimer; Nisha Mani
Journal:  Cureus       Date:  2022-02-10

Review 7.  Multimodality imaging of renal lymphoma and its mimics.

Authors:  Trinh Nguyen; Akshya Gupta; Shweta Bhatt
Journal:  Insights Imaging       Date:  2022-08-13

8.  Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  Johannes Chang; Alexia Dumitrache; Nina Böhling; Jasmin Abu-Omar; Carsten Meyer; Deike Strobel; Julian Luetkens; Andreas Minh Luu; Jürgen Rockstroh; Christian P Strassburg; Jonel Trebicka; Maria A Gonzalez-Carmona; Milka Marinova; Michael Praktiknjo
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

9.  Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol.

Authors:  Jiang Bo; Han Peng; Zhu LianHua; Fei Xiang; Luo YuKun
Journal:  BMC Cancer       Date:  2021-11-02       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.